EASL 2015: Sofosbuvir/ Ledipasvir + Ribavirin Cures Most Hepatitis C Patients with Advanced Liver Disease
An oral regimen of sofosbuvir/ledipasvir (Harvoni) and ribavirin taken for 12 or 24 weeks produced sustained virological response rates of 85%-88% for genotype 1 hepatitis C patients with decompensated cirrhosis and 95%-98% for liver transplant recipients with less advanced liver damage, according to preliminary results from the SOLAR-2 study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress taking place this week in Vienna.
While universal infant hepatitis B virus (HBV) vaccination has already led to major advances in reducing new infections in some settings, further expansion of prevention and treatment are needed to significantly reduce HBV transmission and liver disease mortality, according to an analysis presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress this week in Vienna.
One-pill-a-day HIV treatments such as Atripla, Stribild, Complera, and Triumeq and Triumeq have the same rates of virological failure, drug resistance, and side effects as multiple tablet regimens, according to a meta-analysis presented to the British HIV Association (BHIVA) conference this week in Brighton. Single tablets cost the UK National Health Service (NHS) 5 five times more but have unproven clinical benefits, said Andrew Hill of Chelsea and Westminster Hospital.
There is a strong interest among people living with HIV in research towards an HIV cure, with many potential participants willing to consider antiretroviral treatment interruption. Respondents to a survey presented at the British HIV Association (BHIVA) conference this week in Brighton generally understood that they would be unlikely to benefit personally from cure research. Priorities for a cure were to eliminate health problems and the risk of HIV transmission, rather than necessarily testing HIV-negative.